Loading... Please wait... Loading... Please wait...
ESTIMATED
05/07/2024
05/07/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | $2.15 | $2.15 | $2.15 |
| Q2 2024 | 3 | $1.93 | $2.09 | $2.01 |
| Q3 2024 | 1 | $2.51 | $2.51 | $2.51 |
| Q4 2024 | 1 | $3.53 | $3.53 | $3.53 |
| Q1 2025 | 1 | $2.65 | $2.65 | $2.65 |
| Q2 2025 | 1 | $2.61 | $2.61 | $2.61 |
| Q3 2025 | 1 | $2.83 | $2.83 | $2.83 |
| Q4 2025 | 1 | $3.74 | $3.74 | $3.74 |
| Q1 2026 | 0 | $2.90 | $2.90 | $2.90 |
| Q2 2026 | 0 | $2.80 | $2.80 | $2.80 |
| Q3 2026 | 0 | $2.99 | $2.99 | $2.99 |
| Q4 2026 | 0 | $4.32 | $4.32 | $4.32 |
Bio-Rad Laboratories, Inc. last posted its earnings results on Tuesday, May 7th, 2024. The company reported $2.29 earnings per share for the quarter, topping analysts' consensus estimates of $2.15 by $0.14. The company had revenue of 610.82 M for the quarter and had revenue of 2.67 B for the year. Bio-Rad Laboratories, Inc. has generated $-22 earnings per share over the last year ($-21.82 diluted earnings per share) and currently has a price-to-earnings ratio of -23.82. Bio-Rad Laboratories, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/08/2024 | Q1 2024 | $13.46 | $619.09 M | $610.82 M | 02/16/2024 | Q4 2023 | $12.15 | $685.00 M | $681.18 M | 10/27/2023 | Q3 2023 | $3.65 | $632.12 M | 08/04/2023 | Q2 2023 | -$39.59 | $681.11 M | 05/05/2023 | Q1 2023 | $2.33 | $689.96 M | $676.84 M | 02/17/2023 | Q4 2022 | $27.89 | $742.26 M | $730.29 M | 10/28/2022 | Q3 2022 | -$5.53 | $680.80 M | 07/29/2022 | Q2 2022 | -$31.12 | $691.10 M | 04/29/2022 | Q1 2022 | -$112.58 | $700.06 M | 02/11/2022 | Q4 2021 | -$52.59 | $730.26 M | $732.77 M | 10/29/2021 | Q3 2021 | $131.75 | $664.57 M | $747.05 M | 07/30/2021 | Q2 2021 | $30.71 | $646.07 M | $715.93 M | 04/30/2021 | Q1 2021 | $32.77 | $726.80 M | 02/12/2021 | Q4 2020 | $28.13 | $686.79 M | $789.84 M | 10/30/2020 | Q3 2020 | $44.24 | $570.57 M | $647.26 M | 07/31/2020 | Q2 2020 | $32.59 | $517.06 M | $536.88 M | 05/07/2020 | Q1 2020 | $22.97 | $571.64 M | 03/02/2020 | Q4 2019 | $18.50 | $641.46 M | $624.43 M | 11/01/2019 | Q3 2019 | -$8.68 | $561.40 M | $560.63 M | 08/06/2019 | Q2 2019 | $20.08 | $564.88 M | $572.62 M |
|---|
A. Bio-Rad Laboratories, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based off last year's report dates.
A. In the previous quarter, Bio-Rad Laboratories, Inc. (NYSE:BIO) reported $2.29 earnings per share (EPS) to beat the analysts' consensus estimate of $2.15 by $0.14.
A. The conference call for Bio-Rad Laboratories, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Bio-Rad Laboratories, Inc.'s latest earnings report can be read online.
A. Bio-Rad Laboratories, Inc. (NYSE:BIO) has a recorded annual revenue of $2.67 B.
A. Bio-Rad Laboratories, Inc. (NYSE:BIO) has a recorded net income of $2.67 B. Bio-Rad Laboratories, Inc. has generated $-21.82 earnings per share over the last four quarters.
A. Bio-Rad Laboratories, Inc. (NYSE:BIO) has a price-to-earnings ratio of -23.82 and price/earnings-to-growth ratio is -5.9.
